Research Frontiers Incorporated (NASDAQ:REFR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Joe Harary - President & Chief Executive Officer Conference Call Participants Alan Yakuboff - Kingsview Partners Operator Good afternoon, and welcome to Research Frontiers Investor Conference Call to discuss the Fourth Quarter and Full Year 2024 Results of Operations and Recent Developments. The company will be answering many of the questions that were emailed to it, prior to this conference call either in their presentation or as part of the Q&A session at the end.
Research Frontiers Incorporated (NASDAQ:REFR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Harary - President and CEO Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Third Quarter of 2024 Results of Operations and Recent Developments [Operator Instructions].
WOODBURY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced today that it will release its third quarter 2024 financial results on Thursday, November 7, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 7, 2024 to discuss its third quarter 2024 financial and operating results, as well as recent developments.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.
Research Frontiers, Inc. (NASDAQ:REFR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Joe Harary - President & CEO Conference Call Participants Neal Goldman - Goldman Capital Management Michael Kay - Kay Associates Leonard Lietzow - Private Investor Jeff Harvey - Private Investor Allen Ginsberg - Private Investor Operator Good afternoon ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2024 results of operations and recent developments.
WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.
WOODBURY, NY, July 29, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 1, 2024 to discuss its second quarter 2024 financial and operating results, as well as recent developments.
Research Frontiers Incorporated (NASDAQ:REFR ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Joe Harary – President and Chief Executive Officer Conference Call Participants Ted Campbell – Private Investor Alan Ginsberg – Private Investor Gerald Sherman – Strategic Planning Group Art Brady – Private Investor John Nelson – Private Investor August Berman – Private Investor Mike Zelnick – Private Investor Bruce Denny – Private Investor Jeff Harvey – Private Investor Seth Nickerson – Private Investor Operator Good afternoon, ladies and gentlemen. Welcome to Research Frontiers Investor Conference Call to discuss the Fourth Quarter and Full Year 2023 Results of operations and recent developments.
Research Frontiers Incorporated (NASDAQ:REFR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Joseph Harary - President and CEO Conference Call Participants Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2023 Results of Operations and recent developments.